- Home
- MSLE vs FHTX Comparison
MSLE vs FHTX Comparison
Compare MSLE & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSLE | FHTX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.9M | 173.4M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MSLE | FHTX |
|---|---|---|
| Price | $6.89 | $1.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $24.17 | $4.17 |
| AVG Volume (30 Days) | 62.3K | ★ 1.2M |
| Earning Date | 11-15-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $5.44 | $1.79 |
| 52 Week High | $13.39 | $7.61 |
Technical Indicators
Market Signals| Indicator | MSLE | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.91 | 16.46 |
| Support Level | $5.52 | $1.79 |
| Resistance Level | $10.58 | $5.35 |
| Average True Range (ATR) | 0.58 | 0.25 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 7.94 | 4.66 |
Price Performance
Historical ComparisonAbout MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.